Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News

X4 Pharmaceuticals, Inc

NASDAQ: XFOR · Life Sciences · 5 alerts · CIK 1501697

Share price
$2.83Close, Nov 16
Market cap
$289M
Shares outstanding
102.11MLatest SEC cover page
Sector
Life Sciences
Industry
Biological Products, (No Diagnostic Substances)SIC 2836

Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All X4 Pharmaceuticals, Inc filings on SEC EDGAR ↗

4:07 PM ET 10-Q
Financial Results

X4 Pharmaceuticals Q3 2026 Results: Net Loss of $20.2M, Loss Narrows

X4 Pharmaceuticals reported total revenue of $14.4 million for the first nine months of 2026, a decrease from $32.5 million in the prior year period, primarily due to lower license revenue. Net product revenue from XOLREMDI grew to $7.6 million year-to-date, while the company reduced its nine-month operating loss to $56.7 million through significant cuts in research, development, and administrative expenses.

Key figure
Net loss $20.2M

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.